Probo Medical Completes Acquisition of National Ultrasound

Probo Medical (“Probo”), a leading global provider of medical imaging equipment, parts, repair and service, announced the acquisition of National Ultrasound, Inc. (“National”). Terms of the transaction were not disclosed.

National was founded in 2003 in Duluth, GA and has grown to be one of the largest ultrasound marketing and sales organizations in the country. National has been recognized in the Inc. 5000 list of fastest growing companies for seven consecutive years. Their team brings over 250 years of combined experience working with major ultrasound OEM’s. Over recent years, National has established themselves as a premier provider of ultrasound sales and support to veterinary practices across the country.

“National has a deep history for their sales and marketing prowess, selling new and pre-owned ultrasound equipment to private practices across the country,” said Michael Asmer, CEO of Probo. “They have leveraged that position to expand into the veterinary market.  The opportunity to connect this expertise to our world-class ultrasound sales, service, and repair services is tremendously exciting.”

“National has been a business built on relationships: with our employees, customers and OEM partners.  We found the same values in Probo as we were looking for a partner that could support, and even accelerate, our growth.  The depth, breadth and value proposition of Probo’s offering in ultrasound is second to none and we are excited to share that with our customers,” said Joe Williams, CEO of National.

Probo Medical is backed by Avista Capital Partners, a leading New York-based private equity firm with more than 40 growth-oriented healthcare businesses globally.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy